NewsTradingSentimentCalendarCommunityBriefing
Stocks LIVE

Google Secures Half of Loviisa Nuclear Output

By Stocks Desk · 2026-09-13 · Updated 2026-09-13 05:11 UTC
A large industrial cooling tower with steam rising from the top against a clear sky
Illustration: Tradingbird

Google has locked in a long-term PPA covering half of Loviisa's output to support its Finnish data centers starting in 2028, a move that also triggers plans for new wind and battery infrastructure while exploring further nuclear expansion with Fortum.

  • New details from GN auto stocks/utilities: power plant reveal the deal includes a memorandum of understanding to explore additional nuclear capacity at Loviisa, alongside Google’s concurrent plans for onshore wind and battery storage projects in Finland.

    Source: ans.org
  • Google has signed a long-term power purchase agreement with Fortum to secure 50% of the Loviisa nuclear plant's output, supporting a €1 billion lifetime extension program.

    Source: interestingengineering.com
Based on reporting by interestingengineering.com and ans.org, compiled by the Tradingbird desk.

More from the Stocks desk

All desk stories
  • A metallic turbocharger compressor wheel resting on a dark workbench
    Illustration: Tradingbird

    Garrett Motion Valuation Gap Amid Mixed Price Action

    Garrett Motion trades at a discount to consensus fair value despite recent quarterly declines, driven by a divergence between current earnings multiples and long-term margin expectations.

    2026-09-13
  • A modern hotel lobby with high ceilings and comfortable seating
    Illustration: Tradingbird

    Pebblebrook Hotel Trust Sets October Earnings Date

    Pebblebrook Hotel Trust has scheduled its Q3 2026 results for October 29, maintaining a valuation narrative driven by major urban event pipelines despite recent short-term price softness.

    2026-09-13
  • A clear glass vial standing on a white laboratory bench.
    Illustration: Tradingbird

    ADMA Biologics Faces Earnings Test Amid Share Price Slump

    ADMA Biologics shares have dropped significantly year-to-date, falling 48.4% despite a 20% boost in immunoglobulin output. With a forward P/E of 12.09, the market is currently pricing in caution ahead of the upcoming earnings report.

    2026-09-13